1. Monotherapy with mitotane is recommended in patients after incomplete surgical resection or in patients not fit for surgery or chemotherapy 1 ⊕⊕OO. 2. Monotherapy with mitotane may be recommended in advanced ACC with involvement of few organs and low-grade mitotic index, particularly when RFS after removal of the primary tumor has been longer than 12 months 1 ⊕OOOO. 3. The chemotherapeutic regimen EDP in combination with mitotane is recommended in most patients with advanced or metastatic ACC 1 ⊕⊕⊕⊕. 4. There are insufficient data to recommend a particular targeted therapy in patients with advanced ACC beyond ongoing clinical trials.

Stigliano, A., Chiodini, I., Giordano, R., Faggiano, A., Canu, L., Della Casa, S., Loli, P., Luconi, M., Mantero, F., Terzolo, M., Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE), <<JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION>>, 2016; 39 (1): 103-121. [doi:10.1007/s40618-015-0349-9] [http://hdl.handle.net/10807/172173]

Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE)

L.; Della Casa;
2016

Abstract

1. Monotherapy with mitotane is recommended in patients after incomplete surgical resection or in patients not fit for surgery or chemotherapy 1 ⊕⊕OO. 2. Monotherapy with mitotane may be recommended in advanced ACC with involvement of few organs and low-grade mitotic index, particularly when RFS after removal of the primary tumor has been longer than 12 months 1 ⊕OOOO. 3. The chemotherapeutic regimen EDP in combination with mitotane is recommended in most patients with advanced or metastatic ACC 1 ⊕⊕⊕⊕. 4. There are insufficient data to recommend a particular targeted therapy in patients with advanced ACC beyond ongoing clinical trials.
Inglese
Stigliano, A., Chiodini, I., Giordano, R., Faggiano, A., Canu, L., Della Casa, S., Loli, P., Luconi, M., Mantero, F., Terzolo, M., Management of adrenocortical carcinoma: A consensus statement of the Italian Society of Endocrinology (SIE), <<JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION>>, 2016; 39 (1): 103-121. [doi:10.1007/s40618-015-0349-9] [http://hdl.handle.net/10807/172173]
File in questo prodotto:
File Dimensione Formato  
172173.pdf

non disponibili

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 617.69 kB
Formato Unknown
617.69 kB Unknown   Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10807/172173
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 32
social impact